← Eichor
Study identifier: NCT06095050 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Embolization Treatment of Chronic Refractory Shoulder Tendinopathy

Condition: Shoulder Pain · Tendinopathy · Rotator Cuff Tendinitis  ·  Sponsor: Brigham and Women's Hospital

PhaseNA
Planned participants41
Who can joinAll sexes, 21 Years to 80 Years
Healthy volunteersNo

About this study

This is a randomized controlled trial in which patients with moderate to severe shoulder pain (Visual Analog Scale (VAS) \> 40), in the setting of rotator cuff tendinopathy refractory to conservative treatment, will be enrolled. The primary aim of the study is to estimate the effect of transcatheter arterial embolization (TAE) with physical therapy (PT) vs PT alone on the change in shoulder pain at 12-month follow up. Scientific objectives also include an assessment of safety of the intervention, assessment of changes in Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity score, Shoulder Pain and Disability Index (SPADI) scores, MRI Tendinopathy Score between the TAE + PT and PT groups.

This description comes directly from the study's public registry record.

Talk to the study team

Yan Epelboym, MD, MPH  ·  6177327257  ·  yepelboym@bwh.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Brigham and Women's HospitalBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06095050